The Nexus of COPD, Cardiovascular Disease, and COVID-19: Key Strategies To Optimize Outcomes
Chronic obstructive pulmonary disease (COPD) is a chronic, complex disease with multiple systemic effects, including cardiometabolic conditions, which not only influence patient adherence by adding to the burden of pharmacotherapy, but may also impact COPD therapeutic decisions.
The updated GOLD 2021 COPD guidelines point out several advances for the assessment and treatment of COPD, including the management of COPD patients with comorbidities, and the impact of the ongoing COVID-19 pandemic in COPD management. This interactive infographic activity will walk you through these updated guidelines by using high-impact visuals to summarize the evidence, as well as offer expert perspectives to optimize the management of COPD patients with existing cardiometabolic disease.
This activity is designed for US-based healthcare professionals, including pulmonologists, cardiologists, primary care physicians, nurse practitioners, nurses, physician assistants, and pharmacists.
After completing this activity, the participant should be better able to:
- List the cardiometabolic comorbidities commonly associated with COPD and their impact on COPD management and outcomes
- Apply GOLD 2021 guidelines for the assessment and management of COPD patients with comorbid CVD, based on the latest evidence, efficacy and safety of pharmacotherapies, and patient preferences
- Identify multi-faceted approaches, including effective clinician-patient communication and collaborative multidisciplinary team care, in order to improve the continuity of care and overall outcomes in COPD patients with cardiovascular comorbidities
- Discuss the impact of COVID-19 in patients with COPD and its implications for COPD management
- Review the preventive measures that should be adapted by health professionals while treating COPD patients in the COVID-19 era
Jill Ohar, MD
Professor of Medicine
Wake Forest University School of Medicine
Dr. Ohar discloses the following:
Consulting Fees: BI, GSK, TEVA, AZ Wallace and Graham, Beasely Allan, Hughes Hubbard Garrisin Law Kazan McClein Satterly,& Greenwood
Contracted Research: Sunovion and BI
Don D. Sin, MD, MPH
Professor of Medicine
University of British Columnbia (UBC)
Dr. Sin has nothing to disclose.
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from AstraZeneca.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2624-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period March 10, 2021 through March 10, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.